CANF

Can-Fite BioPharma Ltd.

• NASDAQ·08/17 15:45

  Can-Fite Releases Positive Data For Namodenoson In Treating Pancreatic Cancer

• TipRanks·08/17 11:29

  Can-Fite Reports New Data Supporting Namodenoson Combo Strategy in Pancreatic Cancer

• Benzinga·08/17 11:03

  Can-Fite BioPharma Announces New Preclinical Findings Demonstrating Namodenoson Enhances Anti-Cancer Effect Of Gemcitabine Chemotherapy In Pancreatic Cancer

• TipRanks·08/12 11:28

  Can-Fite BioPharma Advances Phase III Drug Candidates With Strengthened FDA and EMA Pathways

• TipRanks·08/03 11:55

  Can-Fite submits Piclidenoson clinical study protocol to Bambino Gesu

• TipRanks·08/03 11:27

  Can-Fite BioPharma Starts First Piclidenoson Trial in Rare Lowe Syndrome

• Benzinga·08/03 11:03

  Can-Fite BioPharma Submits Phase 2 Clinical Study Protocol To Bambino Gesù Children's Hospital In Rome, Italy, For First Clinical Evaluation Of Piclidenoson In Patients With Lowe Syndrome

• TipRanks·07/20 11:27

  Can-Fite’s Namodenoson Pancreatic Cancer Data Accepted for ESMO 2026 Presentation

• Benzinga·07/20 11:16

  Can-Fite Pancreatic Cancer Data Accepted For ESMO Presentation, To Present Namodenoson Cancer Study Results At The Event

• TipRanks·07/14 20:33

  Can-Fite BioPharma Wins Australian Patent Backing Namodenoson in Liver and Pancreatic Cancer

• TipRanks·07/14 11:15

  Can-Fite BioPharma secures Australian Patent Office allowance for namodenoson

• TipRanks·07/06 11:27

  Can-Fite Completes Key Phase 3 Psoriasis Enrolment Milestone for Piclidenoson

• TipRanks·07/06 11:15

  Can-Fite BioPharma enrolls 247 patients in Piclidenoson trial

• Benzinga·07/06 11:06

  Can-Fite BioPharma Completes Enrolment Of First 247 Patients In Pivotal Phase 3 Study Evaluating Piclidenoson For Treatment Of Moderate-To-Severe Plaque Psoriasis

• Benzinga·07/02 17:05

  11 Health Care Stocks Moving In Thursday's Intraday Session